Esophageal cancer is one of the most harmful upper gastrointestinal cancers, particularly in its advanced stages. Squamous cell carcinoma accounts for approximately 85% of all esophageal cancer cases among Chinese patients and is the main pathological type. Although first-line immunotherapy combined with chemotherapy has improved survival rates for stage IV esophageal squamous cell carcinoma (ESCC), some patients still experience suboptimal local control due to resistance to the treatment regime